Physician

Internal Medicine

Dr. Samuel L. Graham III, MD

Samuel Graham is an expert in the field of Internal Medicine. He went to medical school at Medical University of South Carolina. Doctor Samuel L. Graham III, MD is a published doctor. He published 15 publications, including: 'Discovery of pyrrolidine-based ?-secretase inhibitors: Lead advancement through conformational design for maintenance of ligand binding efficiency.'

Publications

Discovery of pyrrolidine-based ?-secretase inhibitors: Lead advancement through conformational design for maintenance of ligand binding efficiency.
Identification of a novel RAMP-independent CGRP receptor antagonist.
Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in ...
Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase.
Synthesis of the (3R,6S)-3-amino-6-(2,3-difluorophenyl)azepan-2-one of telcagepant (MK-0974), a calcitonin gene-related peptide receptor antagonist for the treatment o...
Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin...
Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-...
Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid.
Macrocyclic inhibitors of beta-secretase: functional activity in an animal model.
Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.
Biochemical and cell-based assays for characterization of BACE-1 inhibitors.
Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

Schools

Medical University of South Carolina
Mc Va Hospital
Med University Sc Hospital
University Louisville Hospital

Doctors Specialties

Internal Medicine

Accepted Insurances

Education

Medical University of South Carolina
Virginia Commonwealth University Health System
Medical University of South Carolina College of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Ashley A. Hammerbeck, MD This Doctor is OpenDoctor Recommended.
	Praveen V. Arla, MPH This Doctor is OpenDoctor Recommended.
	Dr. Eugene Giles Sr., MD This Doctor is OpenDoctor Recommended.
	Dr. Geetika Bhatt, MD
	Dr. Vani Nadar, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel A. Kerr II, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard W. Dowdell, MD This Doctor is OpenDoctor Recommended.
	Dr. Monita R. Chary, MD This Doctor is OpenDoctor Recommended.
	Dr. Akasha A. Haq, MD This Doctor is OpenDoctor Recommended.
	Dr. Sandhya L. Kommana, MD This Doctor is OpenDoctor Recommended.
	Dr. James F. Fitzpatrick, MD This Doctor is OpenDoctor Recommended.
	Dr. Jon M. Bergset, MD
	Dr. Kamal K. Nigam, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert B. Palmer-Ball, MD
	Dr. William M. Schreiber, MD This Doctor is OpenDoctor Recommended.
	Dr. Roberto M. Blankenship, MD
	Dr. Kelley M. McIntyre, MD This Doctor is OpenDoctor Recommended.
	Dr. Harold L. Speevack Jr., MD
	Dr. Amadeo L. Abraham, MD This Doctor is OpenDoctor Recommended.
	Dr. David M. Chambers, MD